Source comparison
Kisspeptin Sermorelin for Hormonal Research: Protocol Comparison
Puberty onset modeling (rodent) 1.0–5.0 nmol/kg SC Not used LH at 60, 90 min GnRH neuron activation threshold Kisspeptin alone sufficient. Adding sermorelin introduces confounding GH effects on gonadal development GH secretagogue potency comparison 1–2 mcg/kg
This comparison does not assign a generated winner or score.
- Puberty onset modeling (rodent)
- 1.0–5.0 nmol/kg SC
- Not used
- LH at 60, 90 min
- GnRH neuron activation threshold
- Kisspeptin alone sufficient. Adding sermorelin introduces confounding GH effects on gonadal development
- GH secretagogue potency comparison
- 1–2 mcg/kg SC
- GH at 30, 60, 90 min
- Peak GH vs area under curve
- Sermorelin's reproducibility superior to GHRP-2 or MK-677 for isolating pituitary-specific response
- Dual-axis crosstalk (clinical)
- 0.24–0.3 nmol/kg IV
- 1 mcg/kg SC
- LH at 60, 90 min; GH at 30, 60 min
- LH/GH ratio correlation
- Requires staggered injection timing and refrigerated sample processing within 15 minutes to prevent hormone degradation
- Ovulation induction research (primate)
- 0.5–1.0 nmol/kg SC daily × 5 days
- LH daily; ultrasound follicle tracking
- Ovarian follicle maturation rate
- Kisspeptin mimics LH surge without exogenous gonadotropins. Sermorelin irrelevant to reproductive outcome
- Age-related GH decline (human)
- GH at 30, 60 min; IGF-1 at 24 hr
- Peak GH and IGF-1 response vs chronological age
- Declining sermorelin response confirms somatotroph senescence. Adding kisspeptin doesn't alter GH secretion in this context
- Administering kisspeptin and sermorelin in the same protocol makes sense only when the research question explicitly involves hypothalamic-pituitary crosstalk between reproductive and somatotropic axes. Single-axis studies should use the relevant peptide in isolation to avoid introducing variables that confound interpretation.